Literature DB >> 23817007

Effects of pirfenidone on increased cough reflex sensitivity in guinea pigs.

Akihito Okazaki1, Noriyuki Ohkura, Masaki Fujimura, Nobuyuki Katayama, Kazuo Kasahara.   

Abstract

Pirfenidone, an antifibrotic drug with anti-inflammatory and antioxidant effects, delays fibrosis in idiopathic pulmonary fibrosis (IPF). Patients with IPF have a greater cough reflex sensitivity to inhaled capsaicin than healthy people, and cough is an independent predictor of IPF disease progression; however, the effects of pirfenidone on cough reflex sensitivity are unknown. After challenge with an aerosolized antigen in actively sensitized guinea pigs, pirfenidone was administered intraperitoneally, and the cough reflex sensitivity was measured at 48 h after the challenge. Bronchoalveolar lavage (BAL) was performed, and the tracheal tissue was collected. Pirfenidone suppressed the capsaicin-induced increase in cough reflex sensitivity in a dose-dependent manner. Additionally, increased levels of prostaglandin E2, substance P, and leukotriene B4, but not histamine, in the BAL fluid were dose dependently suppressed by pirfenidone. The decrease in neutral endopeptidase activity in the tracheal tissue was also alleviated by pirfenidone treatment. The total number of cells and components in the BAL fluid was not influenced. These results suggest that pirfenidone ameliorates isolated cough based on increased cough reflex sensitivity associated with allergic airway diseases, and potentially relieve chronic cough in IPF patients who often have increased cough reflex sensitivity. Prospective studies on cough-relieving effects of pirfenidone in patients with IPF are therefore warranted.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cough reflex sensitivity; Idiopathic pulmonary fibrosis; Neutral endopeptidase; Pirfenidone; Prostaglandin E(2); Substance P

Mesh:

Substances:

Year:  2013        PMID: 23817007     DOI: 10.1016/j.pupt.2013.06.009

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  3 in total

Review 1.  Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis.

Authors:  Yoshito Takeda; Kazuyuki Tsujino; Takashi Kijima; Atsushi Kumanogoh
Journal:  Patient Prefer Adherence       Date:  2014-03-21       Impact factor: 2.711

Review 2.  Cough in Idiopathic Pulmonary Fibrosis.

Authors:  Jennifer Mann; Nicole S L Goh; Anne E Holland; Yet Hong Khor
Journal:  Front Rehabil Sci       Date:  2021-10-18

3.  Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis.

Authors:  Mirjam J G van Manen; Surinder S Birring; Carlo Vancheri; Virginia Vindigni; Elisabetta Renzoni; Anne-Marie Russell; Monique Wapenaar; Vincent Cottin; Marlies S Wijsenbeek
Journal:  Eur Respir J       Date:  2017-10-19       Impact factor: 16.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.